T-BINGEN, GERMANY / BOSTON, MA / ACCESSWIRE / August 20, 2020 / CureVac, a clinically prepared biopharmaceutical company, presents a new elegance of transformer drugs based on messenger ribonucleic acid (“mNSA”), and the European Commission concluded the talks by describing an early acquisition agreement (APA) for our future COVID-19 mNA vaccine.
The proposed contract with the European Commission aims to provide all EU Member States with up to 225 million doses and an option for an additional acquisition of 180 million doses, which will be supplied once our mNR-based vaccine has proven to be effective against COVID-19. [FEMALE.
Our mNR-based candidate vaccine to prevent you from SARS-CoV-2 infection is recently undergoing a Phase 1 clinical trial at various screening sites in Germany and Belgium. The objective is the optimal dose as well as evaluating the protection and immune profile of the vaccine in humans. We expect the first effects in the early fourth quarter of 2020. Based on the effects of the Phase 1 clinical trial, we plan to launch a Phase 2b/3 clinical trial also in the fourth quarter of 2020.
Dr Franz-Werner Haas, Executive Director of CureVac, said: “In the existing pandemic, we are very pleased to join the European Commission’s efforts to provide immediate access to a safe and effective COVID-19 vaccine across Europe. effects of our ongoing clinical trials and regulatory approval, we are fully committed to ensuring broad access to our vaccine.”
About CureVac
CureVac is a global clinical-level biopharmaceutical company in the field of messenger RNA generation (mRNA) with experience in the progression and optimization of this flexible molecule for medical purposes. The precept of CureVac’s patented generation is the use of mRN as a knowledge carrier to require the human body to produce its own proteins capable of combating a wide variety of diseases. The corporation applies its technologies to the progression of prophylactic vaccines, cancer therapies, healing antibodies and the remedy of rare diseases. CureVac is headquartered in Tubingen, Germany, and has offices in Frankfurt and Boston, USA.
Prospective Statements by CureVac
The data presented here are not intended to be complete or imply any data you may wish for. The statements involved herein are made on the date of this document, unless otherwise indicated, and neither the delivery of this document at any time, nor any sale of securities, will in no way create an implication that the data involved in this document is correct at any time. after that date or this data will be updated or revised to reflect the data that is later available or the adjustments that are made after the date of this date.
For more information, please refer to the Company’s reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You can download those documents by visiting EDGAR in the SEC at www.sec.gov.
Media Contact CureVacThorsten Schuller, Director of Corporate Communications CureVac, Tubingen, Germany T: ’49 7071 [email protected]
Investor Relations Contact CureVac Sarah Fakih, Vice President of Investor Relations CureVac, Tubingen, Germany T: ’49 7071 9883-1298M: ‘49160 [email protected]
SOURCE: CureVac AG